INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Va...
PLYMOUTH MEETING, Pennsylvania, June 30, 2020 /PRNewswire-AsiaNet/-- -- INO-4800 Selected for the U.S. Government's Operation Warp Speed -- 94% of Phase 1 trial participants demonstrated overall immune responses at Week 6 after two doses of INO-4800 in trial with 40 healthy volunteers in preliminary analyses
...
Authors: LATEST ASIANET NEWS RELEASES